Visit of Minister for Health & Children -Dr James Reilly

On the 9th of February 2012 Dr James Reilly visited the ICORG Central Office, this was the first time a Minister for Health had done so. In the 75 mins of presentations, discussion and Q & A, the Minister indicated that he was impressed with all the Group had achieved, was extremely supportive of the role of research and the many benefits it brings to a health system, and was keen to see ICORG grow and flourish.

Ireland leads the way in exciting new Lung Cancer Trial

Ireland leads the way in the crizotinib trial with referral from ICORG hospitals all over the country. This has resulted in St. James’s Hospital being the leading European site. All the more exciting when you look at the early data for this drug. In the early phase studies more than 60 percent of lung cancer patients who received crizotinib were alive after two years, according to data released in June 2011.

Nilotinib Leukemia Trial ICORG number 08-02 Completes Accrual

The ICORG 08-02 Nilotinib study has reached its target accrual of 60 patients in May 2011. The last 8 patients were accrued within 8 weeks, just making the mid-May deadline. As a result of this great study teamwork and effort we are able to report on the primary objective for all 60 patients. Upon study completion an abstract has been recently submitted to a top U.S. meeting (American Society of Hematology (ASH)) and we are hopeful that it will be accepted as an oral presentation at the next ASH meeting in December 2011.

American Society of Clinical Oncology (ASCO) Award


A medical oncology registrar, Dr. Greg Korpanty, working with Dr. Bryan Hennessy has just recently won a prestigious merit award from the American Society of Clinical Oncology (ASCO) that will be presented to him at the annual meeting of ASCO in June in Chicago. The award was given for a research project entitled ‘Loss of heterozygosity (LOH) as a measure of whole genome instability in ovarian cancer correlates with clinical outcomes’.
This research will also be highlighted by an expert discussant at the annual meeting in Chicago as one of the outstanding research abstracts submitted to ASCO this year.